In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.
Vivacity-MG3 Trial Confirms Nipocalimab’s Efficacy, Safety in Treating Generalized Myasthenia Gravis
Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...
End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.
Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...
Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include ...
“The goal is to develop life-saving medications for patients faster. That comes down to saving time and money,” said Bonne ...
In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, discusses challenges such as high costs and long ...
Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical ...
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses how EDC and EHR data can be streamlined to ...
In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...
Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback